DOI: 10.1136/ejhpharm-2013-000276.343
View full text |Buy / Rent full text
Sign up to set email alerts

Abstract: Background Everolimus has recently been approved by the European Medicines Agency (EMA) for the treatment of postmenopausal women with advanced breast cancer in combination with exemestane, after treatment failure with letrozole or anastrozole. The approval was based on the results of the BOLERO-2 study. Purpose To compare the use of everolimus plus exemestane in breast cancer in our hospital with the Bolero-2 study. Materials and Methods Retrospective study of all patients treated with everolimus in combi… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles